MEI Pharma Enters Material Definitive Agreement
Ticker: LITS · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Mei Pharma, INC. (LITS) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00000002 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
MEI Pharma just signed a big deal, expect financial moves.
AI Summary
MEI Pharma, Inc. announced on September 3, 2025, the entry into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The company is involved in the pharmaceutical preparations industry.
Why It Matters
This filing signals a significant new contract or financial commitment for MEI Pharma, which could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can introduce new financial obligations and strategic shifts that carry inherent risks.
Key Players & Entities
- MEI Pharma, Inc. (company) — Registrant
- September 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 9920 Pacific Heights Blvd. , Suite 150 San Diego , California 92121 (address) — Principal executive offices
FAQ
What type of material definitive agreement did MEI Pharma, Inc. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on September 3, 2025.
What is the nature of the financial obligation created by this filing?
The filing indicates the creation of a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement' but does not provide specific details on the obligation itself.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 3, 2025.
What is MEI Pharma, Inc.'s Standard Industrial Classification (SIC) code?
MEI Pharma, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where are MEI Pharma, Inc.'s principal executive offices located?
MEI Pharma, Inc.'s principal executive offices are located at 9920 Pacific Heights Blvd., Suite 150, San Diego, California 92121.
Filing Stats: 771 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-09-04 16:31:01
Key Financial Figures
- $0.00000002 — nge on which registered Common Stock, $0.00000002 par value MEIP NASDAQ Indicate by
Filing Documents
- mei8k.htm (8-K) — 27KB
- exhibit10-1.htm (EX-10.1) — 135KB
- 0000929638-25-003398.txt ( ) — 318KB
- meip-20250903.xsd (EX-101.SCH) — 4KB
- meip-20250903_lab.xml (EX-101.LAB) — 21KB
- meip-20250903_pre.xml (EX-101.PRE) — 16KB
- mei8k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 3, 2025, MEI Pharma, Inc. (the "Company"), entered into a master loan agreement (the "Agreement") with BitGo Prime, LLC ("Lender"). The Agreement creates a framework under which the Company may borrow any digital assets or cash from Lender from time to time. Each loan is documented in a separate loan request agreed to by the parties setting forth the specific terms, including principal amount, fees, collateral requirements, and the date on which the loan is to commence and mature. The loan fee, effectively the interest rate on the borrowed amounts, is to be determined for each loan and is calculated on a daily basis at the annualized rate specified in each confirmation. Each loan may have a fixed term, or may include a call option or prepayment option, as specified in each loan request. In general, either party can terminate a loan by providing notice within the time frame set forth in the Agreement. Upon termination, the borrowed digital assets or cash must be returned, and the related collateral released. Borrowings under the Agreement are secured by collateral in favor of the Lender. Collateral may include cash or other forms agreed upon by the Parties. The collateral's required value is typically higher than the borrowed amount, subject to margin calls as set forth in the Agreement. If the value of posted collateral falls below the margin call threshold, the Company must promptly post additional collateral. Failure to maintain sufficient collateral can result in an event of default and remedies available to the Lender, including the right to liquidate pledged collateral. The Agreement contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. The foregoing is a summary of the material terms of the Agreement, and it is qualified in its entirety by reference to the full text of the Agreeme
03
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Exhibit Title 10.1 Master Loan Agreement, dated September 3, 2025, between BitGo Prime, LLC and MEI Pharma, Inc. 104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 4, 2025 By: /s/ Justin J. File Justin J. File Acting Chief Executive Officer, Chief Financial Officer and Secretary